Response to oral azacytidine and romidepsin across study populations
| Response . | All patients (n = 23) . | Treatment-naïve patients (n = 10) . | R/R disease (n = 13) . | tTFH phenotype (n = 15) . | Other subtypes (n = 8) . |
|---|---|---|---|---|---|
| Overall response | 14 (61) | 7 (70) | 7 (54) | 12 (80) | 2 (25) |
| Complete response | 10 (43) | 5 (50) | 5 (38) | 9 (60) | 1 (12.5) |
| Partial response | 4 (17) | 2 (20) | 2 (15) | 3 (20) | 1 (12.5) |
| Stable disease | 5 (22) | 2 (20) | 3 (23) | 2 (13) | 3 (37.5) |
| Progressive disease | 4 (17) | 1 (10) | 3 (23) | 1 (7) | 3 (37.5) |
| Not evaluable | 2 | 2 | 0 | 2 | 0 |
| Response . | All patients (n = 23) . | Treatment-naïve patients (n = 10) . | R/R disease (n = 13) . | tTFH phenotype (n = 15) . | Other subtypes (n = 8) . |
|---|---|---|---|---|---|
| Overall response | 14 (61) | 7 (70) | 7 (54) | 12 (80) | 2 (25) |
| Complete response | 10 (43) | 5 (50) | 5 (38) | 9 (60) | 1 (12.5) |
| Partial response | 4 (17) | 2 (20) | 2 (15) | 3 (20) | 1 (12.5) |
| Stable disease | 5 (22) | 2 (20) | 3 (23) | 2 (13) | 3 (37.5) |
| Progressive disease | 4 (17) | 1 (10) | 3 (23) | 1 (7) | 3 (37.5) |
| Not evaluable | 2 | 2 | 0 | 2 | 0 |
Data are no. (%).